Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Taysha Gene Therapies's TSHA-102?
TSHA-102 is a gene therapy commercialized by Taysha Gene Therapies, with a leading Phase II program in Rett Syndrome. According...